v3.26.3
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Total revenue $ 1,951 $ 1,752 $ 4,973 $ 4,606
Operating expenses        
Research and development 12,500 11,149 34,445 29,081
General and administrative 7,204 8,228 22,563 21,446
Total operating expenses 19,704 19,377 57,008 50,527
Loss from operations (17,753) (17,625) (52,035) (45,921)
Other (expense) income:        
Interest income 649 207 1,174 778
Interest expense (3,090) (1,314) (8,886) (3,856)
Loss on extinguishment of debt 0 0 (2,383) 0
Change in fair value of derivative liability 16,562 0 14,671 0
Other expense, net 34 (1,319) (194) (1,141)
Total other (expense) income 14,155 (2,426) 4,382 (4,219)
Net loss (3,598) (20,051) (47,653) (50,140)
Other comprehensive income (loss)        
Foreign currency translation adjustment 26 46 179 10
Unrealized gain (loss) on available-for-sale debt securities (93) 0 (93) 0
Comprehensive loss (3,665) (20,005) (47,567) (50,130)
Net loss attributable to common shareholders — basic (3,598) (20,051) (47,653) (50,140)
Net loss attributable to common shareholders — diluted $ (3,598) $ (20,051) $ (47,653) $ (50,140)
Weighted shares used in calculating net loss per common share - basic (in shares) 339,214,302 304,003,247 335,188,753 296,066,314
Weighted shares used in calculating net loss per common share - diluted (in shares) 339,214,302 304,003,247 335,188,753 296,066,314
Net loss per share attributable to common shareholders - basic (in USD per share) $ (0.01) $ (0.07) $ (0.14) $ (0.17)
Net loss per share attributable to common shareholders - diluted (in USD per share) $ (0.01) $ (0.07) $ (0.14) $ (0.17)
Collaborative Arrangements        
Total revenue $ 1,951 $ 1,752 $ 4,973 $ 4,606
Operating expenses        
Research and development $ 200 $ 800 $ 1,500 $ 1,900